| Hankinnan lyhyt kuvaus | The object of the procurement was fully automated production capacity based on immunometric analysers to determine human haemoglobin in faeces (immunochemical feacal test; FIT) for colorectal cancer screening. Colorectal cancer screening is based on the Decree of the Finnish Ministry of Social Affairs and Health. The analysis used in screening is based on both the Finnish Cancer Registry's Guide on the organisation of the screening of colorectal cancer (publication of the Finnish Cancer Registry, 2021) and the recommendation of the expert working group appointed by the National Cancer Screening Steering Group (Protocol on the screening of colorectal cancer). Screening samples are taken at home, and they are delivered to the pointed laboratory by mail. Approximately 70-80% of those invited participate in screening, which means they return the faecal sample to the laboratory for analysis. The screening will start in 2022 and it is estimated that during the first year approximately 100 000 samples will be analysed by HUSLAB and 30 000 by ISLAB both in their own hospital districts. The number of samples analysed will increase annually as the age groups invited to screening gradually increase. Estimated number of samples to be analysed in 2027 will be approximately 200,000, of which approximately 150,000 will be analysed by HUSLAB and about 50,000 by ISLAB, both in their own hospital districts. The analysers will be placed in one or more laboratories in HUSLAB and ISLAB. The production capacity was procured using the compensation principle. In addition to analysers, the production capacity included workstations with the necessary software as well as all equipment-related reagents and supplies needed for the intended use, user training and maintenance (proactive fixed-term maintenance and fault maintenance, including travel expenses and spare parts and supplies for maintenance), the sampling device for the screening participants and all the delivery fees. The offered production capacity had to allow undisturbed production during planned maintenance operations. The analysers will be used in HUSLAB by approximately 15 bioanalysts and 4 clinical chemists, and in ISLAB by 10 bioanalysts and 2 clinical chemists. The use of the analysers had to be easy to learn and use, with fault situations easily recognisable. In this competitive tendering, HUSLAB and ISLAB reserved the right to increase production capacity in line with demand during the contract period. The production capacity is calculated in such a way that samples are analysed only on day shifts during weekdays (8 h/day). |
